Oncology Venture ApS has an exclusive license to a computational method to predict patient response to cancer therapies that could provide an efficient and cost-effective way to repurpose compounds that have failed in prior cancer trials and to find new cancer indications for marketed drugs.

The method comprises an undisclosed algorithm that inputs publicly available transcriptomics data from the NCI-60 panel of tumor cell lines and genomics data from about 3,000 patient biopsies. The output is a signature known as a drug response predictor (DRP).